Both responding patients had gone through extensive surgery and had, at the time of treatment initiation, only limited disease burden, suggesting that debulking of tumor-mass may play a role for the outcome of TIL therapy using low-dose IL-2. This evidence concerns the gene IL2 and neoplasm.